Cannabinoid-based Medications for Pain Raymond M. St. Marie, MD; Raphael J. Leo, MA, MD Current Psychiatry, 2021, 20(5), 21-33. Abstract and Introduction Introduction Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.[3] Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As [...]
Lire la suiteClinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078 Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]
Lire la suiteCannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability Francesca Baratta, Marco Simiele, Irene Pignata, Lorenzo Ravetto Enri, Antonio D’Avolio, Riccardo Torta, Anna De Luca, Massimo Collino and Paola Brusa Pharmaceuticals, 2021, 14, 171, 1-13. Doi : 10.3390/ph14020171 Abstract : Current legislation in Italy provides that medical Cannabis may be administered orally or by inhalation. One of the fundamental criteria for the administration of oral formulations is that they deliver a known consistent quantity of the active ingredients to ensure uniform therapies leading to the optimisation of the risks/benefits. In 2018, our group developed an improved Cannabis oil extraction technique. The objective of [...]
Lire la suiteCannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]
Lire la suitePotential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain Marta Vázquez, Natalia Guevara, Cecilia Maldonado, Paulo Cáceres Guido, and Paula Schaiquevich Hindawi, BioMed Research International, 2020, Article ID 3902740, 9 pages Doi : 10.1155/2020/3902740 Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]
Lire la suiteThe Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159 Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]
Lire la suiteMedical Cannabis Use Rising Among Older Adults Pauline Anderson Medscape Medical News ©March 22, 2021 More individuals are using medical cannabis, but the increase appears to be more pronounced among seniors, new research suggests. Results of a large Canadian survey study show that the proportion of older users among total users increased from 17.6% before 2017 to 26.7% in 2018 and 31.2% in 2019. The proportion of older users was 22.7% in 2020, but there were fewer participants in this latest sample (8869 in 2019 and 5644 in 2020). The majority of older respondents reported that they use cannabis to relieve pain and prefer cannabidiol [...]
Lire la suiteCannabis for Pain? An Expert's Guidance John Watson Medscape Neurology © 2021 WebMD, LLC January 05, 2021 Mark Steven Wallace, MD Many have put forth medical cannabis as a promising treatment for chronic pain that can potentially replace opioids. However, although it's never been easier for patients to access medical cannabis, those researching its use say that the structural challenges inherent to studying a Schedule 1 drug remain formidable. Medscape recently spoke with Mark Steven Wallace, MD, a pain management specialist and chair of the Division of Pain Medicine at UC San Diego Health, about the latest data on medical cannabis and the challenges in studying its clinical use in pain [...]
Lire la suiteCannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]
Lire la suite